| Similar Articles |
|---|
 |
The Motley Fool
June 13, 2007
Brian Lawler |
Neurochem Collects the Data Neurochem hints at the data for its Alzheimer's disease drug candidate. The FDA doesn't like data that is hard to interpret, nor is it a fan of retrospective analyses. Investors, take note.   |
The Motley Fool
April 23, 2007
Brian Lawler |
Neurochem Sets Low Expectations The specialty drug developer announces an update on plans to release results from a clinical study. Investors, take note. |
The Motley Fool
April 2, 2008
Brian Lawler |
Following the Drugmaker Formerly Known as Neurochem Neurochem would have been set to hear FDA news on its lead drug candidate Kiacta today, if they had not pulled their marketing application earlier this month. |
The Motley Fool
August 27, 2007
Brian Lawler |
Neurochem Down for the Count? With likely two failed compounds - since the FDA rejected Neurochem's amyloidosis compound Kiacta a second time in July -- it's hard to see much value in shares of the company, considering its bare drug pipeline. |
The Motley Fool
January 31, 2008
Brian Lawler |
When Nutraceuticals Attack After a failed phase 3 trial, Neurochem plans to market Alzhemed as a nutraceutical supplement. |
The Motley Fool
November 14, 2007
Brian Lawler |
Neurochem's Crazy Choice Neurochem chooses a risky path for its lead drug candidate, attempting to have its Alzheimer's disease medication marketed as a dietary supplement. |
The Motley Fool
December 10, 2007
Brian Lawler |
Neurochem's Sure Bet at Failure Investors should add another regulatory date to their biotech calendars, this one regarding Neurochem's lead drug, KIACTA. |
The Motley Fool
July 18, 2007
Brian Lawler |
More Misery for Neurochem It's hard to find another drug developer that has mishandled its correspondence with investors about its drug candidates as badly as Neurochem has over the past year. |
The Motley Fool
December 18, 2007
Brian Lawler |
The Final Nail in Neurochem's Coffin The European Medicines Agency announced its refusal to approve Neurochem's lead drug, KIACTA. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
April 17, 2007
Brian Lawler |
Neurochem Must Wait The FDA delays a regulatory decision on Neurochem's lead compound. Investors, take note. |
The Motley Fool
November 16, 2007
Brian Lawler |
Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note. |
The Motley Fool
September 5, 2008
Brian Lawler |
Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon. |
The Motley Fool
February 8, 2005
Charly Travers |
Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company |
The Motley Fool
May 1, 2007
Mike Havrilla |
Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc. |
BusinessWeek
January 8, 2007
Catherine Arnst |
Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure. |
